CORDIS
EU research results

CORDIS

English EN

Validation of a novel antiviral drug candidate against influenza

Project information

Grant agreement ID: 899835

Status

Ongoing project

  • Start date

    1 April 2020

  • End date

    30 September 2021

Funded under:

H2020-EU.1.1.

Hosted by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Project description

English EN

Novel drugs stop influenza replication

Influenza viruses are responsible for the seasonal flu, affecting millions of people worldwide every year. Given the potential of influenza to cause pandemics with devastating effects on human lives and the economy, there is a pressing need for effective antiviral drugs with a reduced risk of causing viral escape. Scientists of the EU-funded FluAttack project have identified a new family of molecules as potent inhibitors of influenza viruses. These molecules target a cellular function paramount to virus survival and will undergo further testing and characterisation in models of influenza infection. The project aims to support the future development and pre-clinical validation of these anti-flu drugs.

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Research Organisations

EU Contribution

€ 139 081

Beneficiaries (2)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 139 081

CNRS INNOVATION

France

EU Contribution

€ 10 919

Project information

Grant agreement ID: 899835

Status

Ongoing project

  • Start date

    1 April 2020

  • End date

    30 September 2021

Funded under:

H2020-EU.1.1.

Hosted by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France